Tango Therapeutics Inc (TNGX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $22.15 (-5.70%), Market cap $3.25B, 52-week low–high $1.28 ~ $27.77.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017
Financial statements, price targets, institutional (13F) holdings and related news for Tango Therapeutics Inc are updated in real time on BlackAll Trade.
Tango Therapeutics Inc trades at $22.15 (-5.70%). Real-time quotes and charts are available on BlackAll Trade.
Tango Therapeutics Inc has a market cap of about $3.25B.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosi